Liraglutide for HIV-associated Neurocognitive Disorder

Inclusion Criteria: * HIV controlled on therapy for at least 12 weeks * Viral load \< 200 copies * BMI \>27 to 45 * Diagnosis of DM type 2 with A1-C \>7 to 15 * Participants must be willing to comply with all study related procedures Exclusion Criteria: * Personal or family history of pancreatitis * Medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2) * Gastroparesis * Allergy to liraglutide or any of the active ingredients in liraglutide or other GLP-1 analogue * Weight loss drugs other than metformin * Type 1 diabetes mellitus or diabetic ketoacidosis * Known major cognitive deficit dementia, history of head trauma with loss of consciousness \>30 min, history of stroke, current central nervous system (CNS) disorder such as seizures or opportunistic CNS infection * Renal insufficiency defined as creatinine clearance \< 60 mL/min * Active opportunistic infections * Pregnancy or breastfeeding * Unstable cardiovascular disease with hospitalization within 1 year for acute coronary syndrome * Decompensated heart failure * Substance abuse * Active alcohol or opioid substitution therapy * Serious or unstable medical or psychological conditions that would compromise the subject's safety for successful participation